3 results
Primary Objective:To demonstrate that CHF 1535 twice daily is superior to Formoterol twice daily in terms of COPD exacerbations rate during 48 weeks of treatment and in terms of pulmonary function (change in pre-dose morning FEV1 from baseline to 12…
The study will be performed in 3 parts, Parts 1, 2 and 3. In all parts, the purpose is to investigate to what extent APX001 is tolerated. In addition, it will be investigated how quickly and to what extent APX001 is absorbed and eliminated from the…
Part ATo evaluate the safety and tolerability of single and split intravenous doses of Apta-1 in healthy volunteers.Part BTo evaluate the safety and tolerability of split intravenous doses of Apta-1 after LPS infusion in healthy volunteers.